These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1913698)

  • 1. Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).
    Wilding IR; Hardy JG; Davis SS; Melia CD; Evans DF; Short AH; Sparrow RA; Yeh KC
    Clin Neuropharmacol; 1991 Aug; 14(4):305-21. PubMed ID: 1913698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal transit of Sinemet CR in healthy volunteers.
    Wilding IR; Davis SS; Melia CD; Hardy JG; Evans DF; Short AH; Sparrow RA
    Neurology; 1989 Nov; 39(11 Suppl 2):53-8. PubMed ID: 2685651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM; Kutt H; McDowell FH
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical design and development of a Sinemet controlled-release formulation.
    Dempski RE; Scholtz EC; Oberholtzer ER; Yeh KC
    Neurology; 1989 Nov; 39(11 Suppl 2):20-4. PubMed ID: 2685648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
    Roos RA; Tijssen MA; van der Velde EA; Breimer DD
    Clin Neurol Neurosurg; 1993 Sep; 95(3):215-9. PubMed ID: 8242964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
    Hsu A; Yao HM; Gupta S; Modi NB
    J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of continuous-release carbidopa/levodopa.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1994; 17 Suppl 2():S1-6. PubMed ID: 9358189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
    LeWitt PA
    Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.
    Campbell NR; Rankine D; Goodridge AE; Hasinoff BB; Kara M
    Br J Clin Pharmacol; 1990 Oct; 30(4):599-605. PubMed ID: 2291872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
    Bowes SG; Dobbs RJ; Henley M; Charlett A; O'Neill CJ; Nicholson PW; Purkiss AG; Weller C; Dobbs SM
    Eur J Clin Pharmacol; 1992; 43(5):483-9. PubMed ID: 1483485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.
    Sagar KA; Smyth MR
    Analyst; 2000 Mar; 125(3):439-45. PubMed ID: 10829343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J; Schwartz K; Vander Linden C
    Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.